anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A sleeve for holding a contact element 8 against the human skin compromising a tube 2 knitted with elastomeric yarns and tube ends with margins 4 preventing rolling of the tube 2 in on itself. The sleeve may use rubber, polyurethane, silicone, monofilament or microfilament yarns. The contact element 8 may be a trans-dermal treatment patch or an electronic transducer element and the sleeve may include an anti-microbial coil. The margins 4 may take the form of a rib structure or a purl structure which may be knitted with double covered elastomeric yarns. The sleeve may have a pocket 6 for carrying the contact element 8 or the contact element 8 may be integrally knitted into the structure. Suitable dimensions for the margins 4 are also detailed. Also included are a method of construction and use associated with the sleeve.
Participants were subjected to Combined Cognitive Bias Modification in each session. During the attentional bias modification phase, photographs of neutral or threatening (disgusted) faces were used. In each trial, a pair was shown for 500 ms. Then, a sign of arrow appeared and participants were asked to indicate the direction of the arrow. In %80 of the trials, the arrow was in the same area with the neutral photograph. During the interpretational bias modification phase a threatening or positive word, as the interpretation of a sentence, appeared, then, a relevant sentence with ambiguous meaning appeared, and later, participants were asked to indicate if the word and the sentence were related. After their response a feedback (right/wrong) was given and the next trial was started.
Prostatic urethral lift implants will be placed in patients under local anesthesia or monitored anesthetic care. The number of implants used will depend on intra-operative findings, ranging from 2 to 8 implants per patient.
An implantation device includes an elongated tube having a first end portion, an opposing second end portion, and a third tapered portion connecting the first and second end portions. The first end portion includes a first opening and an angled tip. The second end portion includes a second opening, and the second end portion is wider than the first end portion. The implantation device also includes a rod inserted through the first opening and extending out of and away from the first end portion. The rod includes a tapered and rounded end. The second end portion is configured to receive a scleral prosthesis into the second opening and to release the scleral prosthesis from the second opening.
Investigator will attach the ANI monitor V2 (MDoloris Medical Systems, Lille, France) to the patient and monitor Analgesia Nociception Index (ANI) during anesthesia. Remifentanil infusion rate is adjusted according to ANI monitoring. The ANI is adjusted to be between 50 and 70.
A chemiluminescent (CL)-ELISA method with purified and complex antigens of Trypanosoma cruzi is proposed for the specific and sensitive diagnosis of Chagas' disease in patients and blood bank samples. A trypomastigote specific antigen (A & T) together with an epimastigote extract (EpEx), used as a control of sensitivity, are the preparations used. The high sensitivity of the CL-ELISA method permits the use of extremely small amounts of antigen and allows a serum dilution in routine tests as high as 1:2,000, thus reducing the nonspecific or false-positive reactions to a minimum. The use of the A & T purified antigen eliminates cross-reactivities with other infectious agents, detects active infection, and serves to monitor chemotherapy in chronic patients. The use of the EpEx antigenic preparation not only confirms the positive results with A & T but also, in case of discrepancy suggests other infections such as leishmaniasis. In comparison with current tests used in major blood banks, the CL-ELISA method with A & T and EpEx antigens, tested in parallel, proved to be clearly superior either by eliminating indeterminate results or by increasing the statistics of diagnosed positive samples.
Standard clinical treatments established on the basis of the treatment standards of the International Working Group on the Diabetic Foot (IWGDF), in the case of diabetic foot ulcers (2, 3). For ulcers of venous etiology, the treatment standards according to the guidelines of the Spanish Association of Vascular Nursing and Wounds (Asociación Española de Enfermería Vascular y Heridas) will also be applied.
BACKGROUND AND AIMS: Fecal incontinence (FI) is highly prevalent with substantial impacts on quality of life and health care utilization. The impact of obesity on FI remains unclear, with differing conclusions using body mass index (BMI) as a risk factor. We aimed to determine the association between obesity and FI, and whether this relationship is dependent on the distribution of adiposity (waist circumference-to-height ratio [WHtR]).
METHODS: This was a population-based analysis of the National Health and Nutrition Examination Survey, including participants who responded to the bowel health survey in 2005 to 2010. FI was defined by the accidental bowel leakage of solid stool, liquid, or mucus at least once in the past month. Stepwise multivariable logistic regression models were constructed to assess risk factors for FI.
RESULTS: A total of 7606 participants were included, with an overall FI prevalence of 9.2%. When stratified by quartiles of body measurements, FI was increasingly prevalent from the 1st to the 4th quartile for both WHtR (range, 5.3%-12.5%) and BMI (range, 7.1%-10.5%). WHtR was associated with FI and was a stronger predictor than BMI in all quartiles of body measurement. On multivariable analysis, WHtR remained a significant predictor of FI comparing the 4th with the 1st quartile of body measurements (odds ratio [OR], 1.77; 95% confidence interval [CI], 1.11-2.80; P = .017), whereas BMI was not. A WHtR cutoff of >0.592 optimized the Youden index in prediction of FI in the overall sample.
CONCLUSION: WHtR was independently associated with increased odds of FI in this nationally representative sample of United States adults, whereas BMI was not consistently correlated. This suggests bowel continence may depend more on how body mass is distributed.
CT-scan preoperatively, postoperatively and at 3 months, 1 and 2 years. Per-operative navigation based on the CT scan.
The present invention relates to external application Chinese medicine which is applied to medical treatment medicine industry and is used for massage deep penetration therapy. Formulas of a product are radix aconiti, wild aconite, asarum herb, rhizoma arisaematis, tip pimiento and white spirit of 60 DEG. The product has a preparation technology that formula traditional Chinese medicine is selected, cut up, dried, put in a ceramic container and soaked by the white spirit of 60 DEG for 15 days, so the white spirit fully penetrates drugs and becomes brown to perpare medicinal wine, and then, people can use the medicinal wine. The invention has functions of promoting flow of qi, activating blood, expelling blood stasis, dredging channels, dispelling cold and alleviating pain. The channels and acupoints are conduced through vibration and deep penetration on the surface of skins of a human body through the massage deep penetration therapy, so the drugs infiltrate the body through pores of the human body to directly administrate affected parts of organs of the human body. Consequently, the problem that the oral administration of the Chinese medicine generates toxicity for the human body is solved.
The invention discloses a Chinese medicine for treating mammary gland foliole proliferation. The purpose of the invention is to provide the Chinese medicine for treating mammary gland foliole proliferation, which has advantages of fast phyma dissipation, difficult relapse and good curative effect. The medicine decoction is decocted by water with the bulk drugs according to the following weight ratio: 9 to 12 parts of semiaquilegia root, 10 to 20 parts of colter straw, 9 to 12 parts of wild chrysanthemum flower, 10 to 20 parts of honeysuckle flower, 20 to 40 parts of dandelion, 9 to 12 parts of folium citrus reticulatae and 6 to 10 parts of flower bud of Japanese apricot. The present invention has the advantages that the Chinese medicine for treating mammary gland foliole proliferation has functions of clearing heat and detoxifying, detumescence and dissipating binds, coursing the liver and rectifying qi. The medicinal materials can be collected in the south of China. The invention uses a plurality of Chinese herbal medicines for a comprehensive treatment, which has the merits of obvious effect and convenient medicine taking, and the components conform to pharmaceutical administration specifications and have no toxicity or side effect on human bodies.
Men are more likely to experience bothersome Lower Urinary Tract Symptoms (LUTS) as they get older. GPs follow standard processes to investigate signs of cancer, or more serious conditions but do not have access to tools to identify and manage more common symptoms of LUTS. This means men are likely to be referred to a urologist in secondary care, where they will receive advice or treatment that could have been given in primary care if GPs had more access to better diagnostic tools. The PriMUS Study will compare the results of the simple index tests, with the results of the urodynamic reference test, to identify which combination of simple index tests give the best prediction of the urodynamics diagnosis. The top performing simple index tests will be incorporated into the clinical decision support tool so that GPs can manage patients without needing invasive urodynamics. Follow up will be conducted 6 months post involvement; collating the treatment and management decisions made as a result of these procedures. The study will also consider and explore practicalities and acceptability of the urodynamic procedure and clinical decision support tool for both patients and clinical staff by conducting separate qualitative work.
The coronavirus disease 2019 (COVID-19) pandemic substantially impacted different age groups, with children and young people not exempted. Many have experienced enduring health consequences. Presently, there is no consensus on the health outcomes to assess in children and young people with post-COVID-19 condition. Furthermore, it is unclear which measurement instruments are appropriate for use in research and clinical management of children and young people with post-COVID-19. To address these unmet needs, we conducted a consensus study, aiming to develop a core outcome set (COS) and an associated core outcome measurement set (COMS) for evaluating post-COVID-19 condition in children and young people. Our methodology comprised of two phases. In phase 1 (to create a COS), we performed an extensive literature review and categorisation of outcomes, and prioritised those outcomes in a two-round online modified Delphi process followed by a consensus meeting. In phase 2 (to create the COMS), we performed another modified Delphi consensus process to evaluate measurement instruments for previously defined core outcomes from phase 1, followed by an online consensus workshop to finalise recommendations regarding the most appropriate instruments for each core outcome. In phase 1, 214 participants from 37 countries participated, with 154 (72%) contributing to both Delphi rounds. The subsequent online consensus meeting resulted in a final COS which encompassed seven critical outcomes: fatigue; post-exertion symptoms; work/occupational and study changes; as well as functional changes, symptoms, and conditions relating to cardiovascular, neuro-cognitive, gastrointestinal and physical outcomes. In phase 2, 11 international experts were involved in a modified Delphi process, selecting measurement instruments for a subsequent online consensus workshop where 30 voting participants discussed and independently scored the selected instruments. As a result of this consensus process, four instruments met a priori consensus criteria for inclusion: PedsQL multidimensional fatigue scale for "fatigue"; PedsQL gastrointestinal symptom scales for "gastrointestinal"; PedsQL cognitive functioning scale for "neurocognitive" and EQ-5D for "physical functioning". Despite proposing outcome measurement instruments for the remaining three core outcomes ("cardiovascular", "post-exertional malaise", "work/occupational and study changes"), a consensus was not achieved. Our international, consensus-based initiative presents a robust framework for evaluating post-COVID-19 condition in children and young people in research and clinical practice via a rigorously defined COS and associated COMS. It will aid in the uniform measurement and reporting of relevant health outcomes worldwide.
A system and method for managing a crop insurance program facilitates determining an input management plan for application of a crop input to a field within a defined geographic area. A field yield is measured. The field yield pertains to a yield of particular crop associated with a field in a defined geographic area. An aggregate yield is estimated. The aggregate yield relates to the particular crop associated with the defined geographic area. The aggregate yield is scaled to represent a generally equivalent land area to the field. A difference or variation is determined between the field yield and the aggregate yield. The determined difference or indication thereof is made available to a receiving entity (e.g., insurer that is associated with at least one of claims and insurance on the crop in the field).
The identification of carotid atherosclerotic lesion at risk for plaque rupture, eventually resulting in cerebral embolism and stroke, is of paramount clinical importance. High stress in the fibrous plaque cap has been proposed as risk factor. However, among others, residual strains influence said stress predictions, but quantitative and qualitative implications of residual strains in this context are not well explored. We therefore propose a multiplicative kinematics-based Growth and Remodeling (G&R) framework to predict residual strains from homogenizing tissue stress and then investigate its implication on plaque stress. Carotid vessel morphology of four patients was reconstructed from clinical Computed Tomography-Angiography (CT-A) images and equipped with heterogeneous tissue constitutive properties assigned through a histology-based artificial intelligence image segmentation tool. As compared to a purely elastic analysis and depending on patient-specific morphology and tissue distributions, the incorporation of residual strains reduced the maximum wall stress by up to 30 %  and resulted in a fundamentally different distribution of stress across the atherosclerotic wall. Regardless residual strains homogenized tissue stresses, the fibrous plaque cap may persistently be exposed to spots of high stress. In conclusion, the incorporation of residual strains in biomechanical studies of atherosclerotic carotids may be important for a reliable assessment of fibrous plaque cap stress.
This invention proposes a lanolin substitute, capable of absorbing up to at least twice its weight of water or aqueous solution or aqueous suspension. It forms true emulsions, stable over time with a capacity for water absorption superior to that of lanolin. It also possesses the known emollient, moisturizing and occlusive properties of lanolin. This substitute is usable in all the present and future areas of application of lanolin: in the cosmetics industry, dermatology, and in industrial applications (polishes, lubricants). It is obtained by hemi-synthesis from a mixture of unsaturated fatty acids, esters of unsaturated fatty acids, unsaturated hydrocarbons or unsaturated derivatives of the latter and compounds comprising or generating hydroxyl functions, such as glycerol, preferably without a catalyst and in an atmosphere devoid of oxygen. Classical thermal treatment or preferably treatment by dielectric heating.
The invention relates to a method to inhibit bacteria from adhering to a submergible surface. The method contacts the submergible surface with an effective amount of at least one sulfamic acid or salt thereof to inhibit bacterial adhesion to the submergible surface. The invention also relates to a method for controlling biofouling of an aqueous system. This method adds an effective amount of at least one sulfamic acid or salt thereof to inhibit bacteria from adhering to a submerged surface within the aqueous system. This method effectively controls biofouling without substantially killing the fouling organisms. The sulfamic acid used in the method of the invention has the formula R1R2NS(O)2(OH). In this formula, R1 and R2 are independently a hydrogen, a C4-C20 alkyl group or a cyclohexyl group. However, R1 and R 2 are not both hydrogen. Alternatively, R1 and R2, together with the N, may also form a 5-8 membered heterocyclic ring having the formula:In the heterocyclic ring, X is O, NH, or CH2. The salt of sulfamic acid can be an acid salt or quaternized sulfamic acid salt. The present invention also relates to a composition containing sulfamic acids or salts thereof useable in the above methods. The compositions comprise at least one sulfamic acid or salt thereof in an amount effective to inhibit bacteria from adhering to submergible or submerged surfaces.
PURPOSE:A dermal drug for external use, containing one or two or more selected from a plant of the family Nymphaeceae which is a natural raw mate rial or an extract thereof and having improved preventing effect on heat after sunburn, barber's itch, skin roughening, etc. CONSTITUTION:A dermal drug for external use obtained by incorporating powder prepared by powdering a plant of the family Nymphaeceae, e.g. Nuphar japonicum DC. (nuphar rhizome), Nuphar pumilum Smith, Nelumnbo nucifera Gaertn., Brasenia Schreberi J.F. Gmel., etc., or extract obtained by extracting the plant with a solvent, e.g. water, methanol or ethanol, in an amount of 0.001-5wt%, based on the total weight of the dermal drug for external use, dried rhizome or 0.005-10wt% (0.0001-0.2wt% expressed in terms of the weight of the dried material), more preferably 0.01-5wt% (0.0005-0.1wt% expressed in terms of the weight of the dried material), based on the total weight of the dermal drug for external use, rhizome extract with other components. The drug may assume the dosage form, e.g. facial dermal drug for external use such as toilet water, milky lotion, cream or pack, foundation, dispersion, ointment, etc.
This study has two parts. In the single arm phase IIa part, we will enroll 25 patients that have residual Epstein-Barr virus (EBV) DNA after curative radiotherapy or chemoradiotherapy. All patients will receive apatinib. The purpose is to evaluate the disease free-survival (DFS) in these patients treated with apatinib. In the phase IIb part, patients will be randomized to apatinib or placebo in a ratio of 1:1. The estimated sample size is 78 in phase IIb. However, the final sample size in phase IIb will be determined based on results of the phase IIa part.
PURPOSE: To provide a skin agent for external use, containing a plant selected from Stellaria media, Agrimonia pilosa, KANCHIKU, RENSENSOU (whole grass of Glechoma hederacea), SENKINSHI and Spirodela polyrhiza or its extract, exhibiting excellent skin-beautifying effect and aging-prevention effect and having high safety. CONSTITUTION: This skin agent contains one or more kinds of plants selected from Stellaria media, Agrimonia pilosa, KANCHIKU, RENSENSOU, SENKINSHI and Spirodela polyrhiza or its extract as active components in an amount of 0.0001-10wt.%, preferably 0.001-5wt.% in terms of dry solid. It is properly compounded with arbitrary components of conventional skin agent for external use and prepared in the form of milky lotion, cream, face lotion, beauty solution, cleansing cream, pack, cleaning agent, foundation and other dispersed, granular or ointment-formed drugs, quasi-drugs or cosmetic skin agent for external use. The external skin agent prevents the burning sensation, spots, freckles, etc., caused by sunburn.  The extract can be produced by pulverizing the whole grass, leaf, leaf stalk, root, branch, bark, etc., of the above plants as it is or in dried state and extracting the powder with a solvent (e.g. ethanol) at normal temperature or under heating.
Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.
BACKGROUND: IGF2BP3 functions as an RNA-binding protein (RBP) and plays a role in the posttranscriptional control of mRNA localization, stability, and translation. Its dysregulation is frequently associated with tumorigenesis across various cancer types. Nonetheless, our understanding of how the expression of the IGF2BP3 gene is regulated remains limited. The specific functions and underlying mechanisms of IGF2BP3, as well as the potential benefits of targeting it for therapeutic purposes in bladder cancer, are not yet well comprehended.
METHODS: The mRNA and protein expression were examined by RT-qPCR and western blotting, respectively. The methylation level of CpG sites was detected by Bisulfite sequencing PCR (BSP). The regulation of IGF2BP3 expression by miR-320a-3p was analyzed by luciferase reporter assay. The functional role of IGF2BP3 was determined through proliferation, colony formation, wound healing, invasion assays, and xenograft mouse model. The regulation of HMGB1 by IGF2BP3 was investigated by RNA immunoprecipitation (RIP) and mRNA stability assays.
RESULTS: We observed a significant elevation in IGF2BP3 levels within bladder cancer samples, correlating with more advanced stages and grades, as well as an unfavorable prognosis. Subsequent investigations revealed that the upregulation of IGF2BP3 expression is triggered by copy number gain/amplification and promoter hypomethylation in various tumor types, including bladder cancer. Furthermore, miR-320a-3p was identified as another negative regulator in bladder cancer. Functionally, the upregulation of IGF2BP3 expression exacerbated bladder cancer progression, including the proliferation, migration, and invasion of bladder cancer. Conversely, IGF2BP3 silencing produced the opposite effects. Moreover, IGF2BP3 expression positively correlated with inflammation and immune infiltration in bladder cancer. Mechanistically, IGF2BP3 enhanced mRNA stability and promoted the expression of HMGB1 by binding to its mRNA, which is a factor that promotes inflammation and orchestrates tumorigenesis in many cancers. Importantly, pharmacological inhibition of HMGB1 with glycyrrhizin, a specific HMGB1 inhibitor, effectively reversed the cancer-promoting effects of IGF2BP3 overexpression in bladder cancer. Furthermore, the relationship between HMGB1 mRNA and IGF2PB3 is also observed in mammalian embryonic development, with the expression of both genes gradually decreasing as embryonic development progresses.
CONCLUSIONS: Our present study sheds light on the genetic and epigenetic mechanisms governing IGF2BP3 expression, underscoring the critical involvement of the IGF2BP3-HMGB1 axis in driving bladder cancer progression. Additionally, it advocates for the investigation of inhibiting IGF2BP3-HMGB1 as a viable therapeutic approach for treating bladder cancer.